Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study

Caffo O;De Giorgi U;Fratino L;Alesini D;Zagonel V;Facchini G;Gasparro D;Ortega C;Tucci M;Verderame F;Campadelli E;Lo Re G;Procopio G;Sabbatini R;Donini M;Morelli F;Sartori D;Zucali P;Carrozza F;D'Angelo A;Vicario G;Massari F;Santini D;Sava T;Messina C;Fornarini G;La Torre L;Ricotta R;Aieta M;Mucciarini C;Zustovich F;Macrini S;Burgio SL;Santarossa S;D'Aniello C;Basso U;Tarasconi S;Cortesi E;Buttigliero C;Ruatta F;Veccia A;Conteduca V;Maines F;Galligioni E.

2015-01-01